Know Cancer

or
forgot password

A Randomized, Open Label, Single Dose, Crossover Study to Assess Bioequivalence of Doxorubicin Hydrochloride Liposome Injection 2 mg/mL in Patients With Ovarian Cancer


Phase 1
18 Years
N/A
Not Enrolling
Female
Ovarian Carcinoma

Thank you

Trial Information

A Randomized, Open Label, Single Dose, Crossover Study to Assess Bioequivalence of Doxorubicin Hydrochloride Liposome Injection 2 mg/mL in Patients With Ovarian Cancer


Inclusion Criteria:



- Subjects meeting all of the following criteria will be considered for enrollment in
the study:

- Availability of subject for the entire study period and willingness to adhere to
protocol requirements.

- Patients with documented diagnosis of Ovarian Cancer and eligible for receiving
a dose 50mg/m2 of Doxorubicin liposome(preferably on no other concomitant
medication, however, if considered necessary, to be documented and given).

- Patients at least 18-years of age or older. iv. Subjects who have no evidence of
underlying disease (except ovarian cancer) during screening medical history and
whose physical examination is performed within 21 days prior to commencement of
the study.

- Patients with Performance ≤ 2 on the ECOG performance scale. vi. Subjects whose
screening laboratory values are within normal limits or considered by the
clinical Investigator/Co-Investigator to be of no clinical significance.

- Informed consent form given in written form.

Exclusion Criteria:

- History or presence of significant:

- Allergy or Significant history of hypersensitivity or idiosyncratic
reactions to Doxorubicin Hydrochloride and/or any related compounds etc.

- Cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine,
immunologic, dermatologic, musculoskeletal, neurological or psychiatric disease.

- Alcohol dependence, alcohol abuse or drug abuse or addiction with any
recreational drug within past one year.

- Clinically significant illness (except ovarian cancer)within 4 weeks before the
start of the study v. Positive result to HIV, HCV, RPR and HBsAg.

- Use of enzyme-modifying drugs (like Phenytoin, Carbamazepine, Barbiturates,
Gresiofulvine etc.) in the previous 30 days before day 1 of this study and
during the study.

- Donation of 350 mL or more of blood in the previous 90 days before day 1 of this
study.

- Participation in another clinical trial within the preceding 90 days of study start

- Subjects who have:

- Systolic blood pressure less than 90 mm of Hg or more than 140 mm of Hg

- Diastolic blood pressure less than 60 mm of Hg or more than 90 mm of Hg

- Pulse rate below 60/min. or above 100/min

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label

Outcome Measure:

90% confidence interval of the relative mean Cmax, AUC0-t, AUC0-∞, of the test and reference product

Outcome Time Frame:

2 cycles

Safety Issue:

No

Authority:

United States: Food and Drug Administration

Study ID:

DOX_2I_1476_09

NCT ID:

NCT00862355

Start Date:

March 2010

Completion Date:

January 2011

Related Keywords:

  • Ovarian Carcinoma
  • Carcinoma
  • Ovary
  • Doxorubicin
  • Carcinoma Ovary
  • Carcinoma
  • Ovarian Neoplasms
  • Neoplasms, Glandular and Epithelial

Name

Location